CEACAM5, CEA cell adhesion molecule 5, 1048

N. diseases: 428; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE There were significant differences in age, gender, carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 153 between gastric cancer and healthy controls (<i>P</i><0.05). 31308753 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE Combined measurement of SYT13 and CEA mRNA levels in peritoneal lavage fluid could serve as a promising approach to predict peritoneal recurrence of GC. 31055693 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE It is advantageous to use both CEA level and the CONUT score to assess the prognosis of patients with gastric cancer, which reflect both tumor-related factors and host-related factors, respectively. 30838449 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Data from receiver operating characteristic (ROC) curve analysis disclosed a better diagnostic accuracy of plasma DEK than carcinoembryonic antigen (CEA), carbohydrate antigen 19.9 (CA 19.9), and C-reactive protein (CRP), highlighting its potential as an effective plasma biomarker for GC. 31766266 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Combination of ADAM 8 and CEA further increased the diagnostic accuracy to predict GC (sensitivity, 81.8%; specificity, 84.0%). 31347325 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE <b>Results:</b> Univariate analysis showed that the factors related to PD in GC were: carbohydrate antigen (CA) 125 (<i>P</i> < 0.0001), CA19-9 (<i>P</i> < 0.0001), CA72-4 (<i>P</i> < 0.0001), FLR (<i>P</i> < 0.0001), neutrophil-to-lymphocyte ratio (NLR) (<i>P</i> < 0.0001), albumin-to- lymphocyte ratio (ALR) (<i>P</i> < 0.0001), platelet-to-lymphocyte ratio (PLR) (<i>P</i> = 0.013), and carcinoembryonic antigen (CEA) (<i>P</i> = 0.031). 31750248 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Associations between FITC, CEA, NLR, foxp3+ Treg lymphocytes (both 1- and 3-year OS), CA 19-9, or VEGF and GC OS were supported by highly suggestive evidence, however, the results should be interpreted cautiously due to inadequate methodological quality as deemed by AMSTAR 2.0. 31850212 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Whereas NLR, PLR and CEA are known to help distinguish GC from benign gastric lesions, combining CEA with PLR or NLR offers better diagnostic value for GC than any of them used alone. 29476736 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Currently, CEA, CA50 and CA72-4 are commonly used as tumor markers for gastric cancer by immunoassays. 30303958 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE We developed a dual-label time-resolved fluoroimmunoassay (TRFIA) to simultaneously detect carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA) in human serum to aid the diagnosis and prognosis of gastric cancer. 29729233 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE In a subgroup analysis based on TNM stage, preoperative CEA/CA19-9 levels clearly stratified the survival rates for stage III GC (p < 0.05). 29971670 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE This study aims to evaluate and compare the diagnostic accuracy of 5 common tumor biomarkers (CA19-9, CA125, PG, IncRNA, and DNA methylation) and CEA and their combinations for diagnosing gastric cancer through network meta-analysis method, and to rank these tests using a superiority index. 29742692 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE sLAG3 in PB was poorly expressed and its expression was positively correlated with IL-12 and IFN-γ expression in GC patients. sLAG3 was proved to have a higher diagnostic value than CEA in GC. 30223387 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE Serum TK1, CA 19-9, CA 72-4 and CEA levels were measured in 169 patients with GC, 344 patients with CRC and 75 healthy controls using electro-chemiluminescence. 29483954 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE The aim of this study was to evaluate the significance of perioperative serum levels of CEA and CA19-9 for predicting the recurrence and long-term survival after patients with pT2-4 GC undergo curative gastrectomy. 28441659 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE Survival analysis showed that large tumor size (>5 cm), elevated preoperative serum carcinoembryonic antigen (CEA) level, advanced TNM stage and high CXCR6 expression indicated worse overall survival (OS) and disease-free survival (DFS) in GC, and CXCR6 was an independent predictor for both OS and DFS in GC. 28440473 2017
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE The serum miR-503 level in GC was inversely correlated with carcinoembryonic antigen (CEA) (<i>r</i>=-0.624, <i>P</i><0.001). 28096682 2017
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Compared with CEA, CA19-9, CA72-4 and CA50, CFD may prove to be a better biomarker for the screening of GC, thus providing a sensitive biomarker for screening and monitoring progression of GC. 28903321 2017
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE The PNI and serum levels of CEA and CA19-9 of 453 patients with GC were measured to examine correlations between those levels and patients' prognoses. 28293741 2017
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE In conclusion, combined use of MPV, PDW and CEA can accurately distinguish gastric cancer from gastric ulcer and controls. 28977972 2017
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Multivariate survival analysis showed that CEA (OR = 4.924), and T category (OR = 2.214) were significant prognostic factors for stage pN<sub>0</sub> GC (all <i>P</i> < 0.05). 29358864 2017
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 AlteredExpression disease BEFREE Carcinoembryonic antigen (CEA) is a classic tumor-specific antigen that is overexpressed in several cancers, including gastric cancer. 28211613 2017
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Furthermore, CEACAM6 may serve as a better marker for predicting OS in GC than CEA. 28883649 2017
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE The positive rate for a diagnosis of GC increased from 16.3% to 29.3% when S-p53-Ab was combined with CEA in this study. 28373470 2017
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.100 Biomarker disease BEFREE Although carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 are the most commonly used tumor markers in gastric cancer, the differences in the characteristics of these two markers remain unclear, because most previous studies have included many patients who were positive for both markers. 27566604 2017